BSH 2022 | Genetic predispositions to MDS
Daniel Wiseman
• 4 Apr 2022
Daniel Wiseman, MBChB, MRCP, FRCPath, PhD, University of Manchester, Manchester, UK, discusses genetic predispositions to myelodysplastic syndromes (MDS). A growing number of mutations associated with the development of MDS are being identified, including RUNX1, DDX41, and ETV6. It is important for clinicians to consider this genetic risk, and take the family history of every patient in order to examine the risk of a genetic predisposition. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.
Disclosures
Aster – received funding
